APVO

NASD Aptevo Therapeutics, Inc.

Nov 3, 2026 · 1:11 PM ET DELAYED Market Open

$1.32 ↓ -0.03 (-2.22%) Trading Down from the previous close of $1.35, $0.12 below the day’s high of $1.44

YTD change: -86.00%
vs 20-day SMA: -17.52%
vs 200-day SMA: -69.51%

Price ranges

Previous day

$1.33 $1.40

open $1.36 close $1.35

-$0.01 (-0.74%)

Today

$1.32 $1.44

open $1.35 now $1.32

-$0.03 (-2.22%)

Past week

$1.25 $1.58

from $1.50 now $1.32

-$0.18 (-12.00%)

Past month

$1.25 $1.97

from $1.80 now $1.32

-$0.48 (-26.67%)

This year

$1.25 $10.70

from $9.43 now $1.32

-$8.11 (-86.00%)

Price & Performance

-4.10 (-75.23%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor

The stock is 100.0% away from all-time highs of $287,179.00
APVO is down 86% since the beginning of the year
APVO is down 95% over the past 12 months
APVO is down 27% over the past 1 month
4% of all APVO investors are betting against APVO

APVO reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -8.2%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-5.31

Earnings momentum -42.9% Quarterly EPS growth

Quarterly change -42.9%

Valuation

P/E ratio 0.02

Enterprise value $-3972910.0

Beta 2.55

Balance sheet & scale

IncomeN/A

RevenueN/A

Cash$9.8M

Debt$4.2K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Professional, Scientific, and Technical Services

Industry Group Scientific Research and Development Services

Market cap $3.5M

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Competitor comparison

Ticker	Company	Price	Change
AMGN	Amgen Inc.	$465.45	-0.12%
MRNA	Moderna, Inc.	$220.83	-0.40%
RVMD	Revolution Medicines, Inc.	$188.17	-1.64%
ROIV	Roivant Sciences Ltd.	$35.89	-2.76%
BNTX	BioNTech SE Sponsored ADR	$87.53	-0.73%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.